Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary)
- Indications Diabetic nephropathies; Proteinuria
- Focus Therapeutic Use
- Sponsors Mallinckrodt Inc.; Questcor Pharmaceuticals
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.
- 09 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Nov 2013 Planned end date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.